Zimberelimab
- Generic Name
- Zimberelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2259860-24-5
- Unique Ingredient Identifier
- ZBL7O904IL
- Indication
用于治疗二线以上复发或难治性经典型霍奇金淋巴瘤（r/r cHL）患者。
- Associated Conditions
- -
- Associated Therapies
- -
Domvanalimab and Zimberelimab in Advanced Liver Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 58
- Registration Number
- NCT05724563
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT05688215
- Locations
- 🇺🇸
Yonemoto,Lisa, Los Angeles, California, United States
Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 320
- Registration Number
- NCT05676931
- Locations
- 🇮🇹
Azienda Sanitaria Territoriale Pesaro Urbino (AST PU), Pesaro, Italy
🇮🇹Fondazione IRCCS Istituto Nazionale dei tumori di Milano, Rome, Italy
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 1040
- Registration Number
- NCT05568095
- Locations
- 🇺🇸
UCLA Ronald Reagan Med Ctr, Santa Monica, California, United States
🇺🇸Smillow Cancer Hosp, New Haven, Connecticut, United States
🇺🇸Regions Hospital, Saint Louis Park, Minnesota, United States
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 792
- Registration Number
- NCT05502237
- Locations
- 🇦🇷
Clínica Viedma, Viedma, Argentina
🇦🇹Klinikum Klagenfurt am Woerthersee, Klagenfurt Am Woerthersee, Austria
🇺🇸Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States
Switch Maintenance in Pancreatic
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- James Cleary, MD, PhD
- Target Recruit Count
- 46
- Registration Number
- NCT05419479
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05335941
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT05329766
- Locations
- 🇰🇷
Asan Medical Center Hospital, Seoul, Korea, Republic of
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05177770
- Locations
- 🇺🇸
START South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸START Mountain Region, Utah Cancer Specialists, West Valley City, Utah, United States
🇨🇦BC Cancer - The Vancouver Centre, Vancouver, British Columbia, Canada
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Diwakar Davar
- Target Recruit Count
- 26
- Registration Number
- NCT05130177
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.